A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations

Gynecologic Oncology

Volumn 109, Issue 2, 2008, Pages 168-173

  Folkins, Ann K ^a   Jarboe, Elke A ^a   Saleemuddin, Aasia ^a   Lee, Yonghee ^c   Callahan, Michael J ^a   Drapkin, Ronny ^b   Garber, Judy E ^b   Muto, Michael G ^a   Tworoger, Shelley ^a   Crum, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

BRCA; Carcinogenesis; Fallopian tube neoplasms; Ovarian neoplasms; p53; Precancer; Precursor; Serous carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; DNA DAMAGE; EARLY CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PELVIS CANCER; PRECANCER; PRIORITY JOURNAL; SECRETORY CELL; UTERINE TUBE CARCINOMA;

ADNEXA UTERI; ADULT; AGED; CARCINOMA; CYSTS; DNA DAMAGE; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; MIDDLE AGED; MUTATION; OVARIAN DISEASES; OVARY; PELVIC NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42949138321     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.012     Document Type: Article

References (28)

1. Quirk J.T., Natarajan N., and Mettlin C.J. Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol Oncol 99 (2005) 248-250
2. Deligdisch L., Gil J., Kerner H., Wu H.S., Beck D., and Gershoni-Baruch R. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 86 (1999) 1544-1550
3. Bell D.A., and Scully R.E. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 73 (1994) 1859-1864
4. Scully R.E., Young R.H., and Clement P.B. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. American Registry of Pathology, AFIP (1998) 51-79
5. Hutson R., Ramsdale J., and Wells M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 27 (1995) 367-371
6. Barakat R.R., Federici M.G., Saigo P.E., Robson M.E., Offit K., and Boyd J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 89 (2000) 383-390
7. Piek J.M., Van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H., et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195 (2001) 451-456
8. Piek J.M., Kenemans P., and Verheijen R.H. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 191 (2004) 718-732
9. Finch A., Shaw P., Rosen B., Murphy J., Narod S.A., and Colgan R.J. Clinical and pathology findins of prophylactic salpingo-oophorectomies in 159 BRCA 1 and BRCA 2 carriers. Gynecol Oncol 100 (2006) 58-64
10. Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., Garber J.E., Cramer D.W., and Crum C.P. The Tubal Fimbria is a Preferred Site for Early Adenocarcinoma in Women with Familial Ovarian Cancer Syndrome. Am J Surg Pathol 30 2 (2006) 230-236
11. Cass I., Holschneider C., Datta N., Barbuto D., Walts A.E., and Karlan B.Y. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol 106 (2005) 1327-1334
12. Kindelberger D., Lee Y., Miron A., et al. Intra-epithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31 (2007) 161-169
13. Schlosshauer P.W., Cohen C.J., Penault-Llorca F., Miranda C.R., Bignon Y.J., Dauplat J., et al. Prophylactic oophorectomy. Cancer 98 12 (2003 Dec) 2599-2606
14. Lee Y., Miron A., Drapkin R., Nucci M.R., Medeiros F., Saleemuddin A., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 21126-21135
15. Thiriet C., and Hayes J.J. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 18 (2005) 617-622
16. Fernandez-Capetillo O., Lee A., Nussenzweig M., and Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst) 3 (2004) 959-967
17. Rios-Doria J., Fay A., Velkova A., and Monteiro A.N. DNA damage response: determining the fate of phosphorylated histone H2AX. Cancer Biol Ther 5 (2006) 142-144
18. Motoyama N., and Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14 (2004) 11-16
19. Callahan M.J., Crum C.P., Medeiros F., Kindelberger D.W., Elvin J.A., Garber J.E., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 25 (2007) 3985-3990
20. Piek J.M., Torrenga B., Hermsen B., Verheijen R.H., Zweemer R.P., Gille J.J., et al. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. Fam Cancer 2 (2003) 73-78
21. Werness B.A., Ramus S.J., DiCioccio R.A., Whittemore A.S., Garlinghouse-Jones K., Oakley-Girvan I., et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 23 1 (2004 Jan) 29-34
22. Kerner R., Sabo E., Gershoni-Baruch R., Beck D., and Ben-Izhak O. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. Gynecol Oncol 99 2 (2005 Nov) 367-375
23. Murdoch W.J., and Martinchick J.F. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 229 (2004) 546-552
24. Zhang Z., Singh M., Davidson S., Rosen D.G., Yang G., and Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol 20 (2007) 1078-1084
25. Chung C.M., Man C., Jin Y., Jin C., Guan X.Y., Wang Q., et al. Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 43 (2005) 165-174
26. Mutter G.L., Ince T.A., Baak J.P., Kust G.A., Zhou X.P., and Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 61 (2001) 4311-4314
27. Easton D.F., Ford D., and Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet 56 (1995) 265-271
28. Piek J.M., van Diest P.J., Zweemer R.P., Jansen J.W., Poort-Keesom R.J., Menko F.H., et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195 (2001) 451-456